Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 36
- Registration Number
- NCT06687772
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 20
- Registration Number
- NCT06680661
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Xianmin Song, MD
- Target Recruit Count
- 50
- Registration Number
- NCT06468267
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06252870
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Brest, Brest, France
🇫🇷CHU Nantes, Nantes, France
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Dual-Energy Computed TomographyProcedure: EchocardiographyDrug: FludarabineProcedure: Magnetic Resonance ImagingDrug: MelphalanProcedure: Multigated Acquisition ScanBiological: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201Drug: TacrolimusDrug: ThiotepaRadiation: Total Marrow and Lymphoid Irradiation
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT06195891
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CarboplatinDrug: CisplatinProcedure: Computed TomographyDrug: CyclophosphamideBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideProcedure: FDG-Positron Emission Tomography and Computed Tomography ScanProcedure: Hematopoietic Cell TransplantationDrug: IrinotecanDrug: IsotretinoinProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingDrug: MelphalanRadiation: Radiation TherapyProcedure: Radionuclide ImagingOther: Survey AdministrationDrug: TemozolomideDrug: ThiotepaDrug: TopotecanProcedure: Tumor ResectionDrug: Vincristine
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 478
- Registration Number
- NCT06172296
- Locations
- 🇺🇸
Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Conditions
- Interventions
- Drug: Rabbit Anti thymocyte globulinDrug: PlerixaforBiological: Granulocyte Colony-Stimulating FactorDrug: BusulfanDrug: FludarabineDrug: ThiotepaDrug: MelphalanBiological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graftBiological: memory-like natural killer cellsBiological: IL-2Device: CliniMACS
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06158828
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Conditions
- Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmHematopoietic and Lymphoid System NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaChronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirateDrug: CyclophosphamideDrug: CyclosporineProcedure: Diagnostic ImagingProcedure: EchocardiographyDrug: Fludarabine PhosphateProcedure: Multigated Acquisition ScanDrug: Mycophenolate MofetilOther: Survey AdministrationDrug: ThiotepaRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06013423
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05854225
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT05579769
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.